What's the problem? [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2017-07-11 14:43  – Posting: # 17533
Views: 15,877

Hi all,
Recently we did pilot and pivotal (Partial reference replicate) studies for WHO and we got high variability (CV=32%). In the USFDA product specific guidance they have suggested 2x2 crossover design for this drug. Based on our prior experience can we perform reference replicate study or need to go as per guidance?:confused:

Kumar Naidu

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,271 posts in 4,099 threads, 1,315 registered users;
online 15 (0 registered, 15 guests [including 11 identified bots]).

It’s easy to lie with statistics;
it is easier to lie without them.    Frederick Mosteller

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5